Developing the next generation of vaccinologists

Gregory A. Poland; Myron M. Levine

doi:10.1016/j.vaccine.2010.11.001

Developing the next generation of vaccinologists

Gregory A. Poland, Myron M. Levine

General Internal Medicine

Research output: Contribution to journal › Editorial › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	8227-8228
Number of pages	2
Journal	Vaccine
Volume	28
Issue number	52
DOIs	https://doi.org/10.1016/j.vaccine.2010.11.001
State	Published - Dec 6 2010

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.11.001

Cite this

@article{dbeeb23efe1e4ba6b71dbebb63901590,

title = "Developing the next generation of vaccinologists",

author = "Poland, {Gregory A.} and Levine, {Myron M.}",

note = "Funding Information: Within the United States for example, only one formally organized academic program in vaccine sciences exists. This program is an NIH-funded (T32) vaccinology training grant at the Center for Vaccine Development (CVD) at the University of Maryland. The program (which typically involves 3–4 years of post-doctoral training), includes three distinct tracks. One track provides training in basic research involving the stage of discovery and preparation of vaccine candidates through animal model evaluation and accumulation of the pre-clinical data necessary to support an Investigational New Drug application to the U.S. FDA to undertake “first in humans” clinical trials. A second track involves training in the design and performance of Phase 1 and 2 clinical trials, including intensive didactic and practical instruction in Good Clinical Practices, maintenance of INDs and strategies and options for paths to licensure. A third track involves the design and performance of large-scale Phase 3 pre-licensure efficacy trials and Phase 4 post-licensure studies to assess the impact and safety of vaccines when implemented in large populations; this track includes training in data management, analysis and biostatistics. The NIH-funded Vaccinology Training Program interacts with other activities within CVD, such as basic research projects supported by R01 and other grants, clinical trials of various vaccines supported by a NIH Vaccine and Treatment Evaluation Unit, N01 research contracts, various basic and translational projects supported by the Middle Atlantic Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research, and field epidemiologic and vaccine field trial studies supported by the Bill and Melinda Gates Foundation, including at CVD's field units in Mali, Chile and Malawi. A limitation of the T32 grant is its restriction to U.S. citizens or permanent residents. Therefore, trainees from abroad are supported by other sources of training funds. ",

year = "2010",

month = dec,

day = "6",

doi = "10.1016/j.vaccine.2010.11.001",

language = "English (US)",

volume = "28",

pages = "8227--8228",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "52",

}

TY - JOUR

T1 - Developing the next generation of vaccinologists

AU - Poland, Gregory A.

AU - Levine, Myron M.

N1 - Funding Information: Within the United States for example, only one formally organized academic program in vaccine sciences exists. This program is an NIH-funded (T32) vaccinology training grant at the Center for Vaccine Development (CVD) at the University of Maryland. The program (which typically involves 3–4 years of post-doctoral training), includes three distinct tracks. One track provides training in basic research involving the stage of discovery and preparation of vaccine candidates through animal model evaluation and accumulation of the pre-clinical data necessary to support an Investigational New Drug application to the U.S. FDA to undertake “first in humans” clinical trials. A second track involves training in the design and performance of Phase 1 and 2 clinical trials, including intensive didactic and practical instruction in Good Clinical Practices, maintenance of INDs and strategies and options for paths to licensure. A third track involves the design and performance of large-scale Phase 3 pre-licensure efficacy trials and Phase 4 post-licensure studies to assess the impact and safety of vaccines when implemented in large populations; this track includes training in data management, analysis and biostatistics. The NIH-funded Vaccinology Training Program interacts with other activities within CVD, such as basic research projects supported by R01 and other grants, clinical trials of various vaccines supported by a NIH Vaccine and Treatment Evaluation Unit, N01 research contracts, various basic and translational projects supported by the Middle Atlantic Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research, and field epidemiologic and vaccine field trial studies supported by the Bill and Melinda Gates Foundation, including at CVD's field units in Mali, Chile and Malawi. A limitation of the T32 grant is its restriction to U.S. citizens or permanent residents. Therefore, trainees from abroad are supported by other sources of training funds.

PY - 2010/12/6

Y1 - 2010/12/6

UR - http://www.scopus.com/inward/record.url?scp=78649743324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649743324&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.11.001

DO - 10.1016/j.vaccine.2010.11.001

M3 - Editorial

C2 - 21129602

AN - SCOPUS:78649743324

SN - 0264-410X

VL - 28

SP - 8227

EP - 8228

JO - Vaccine

JF - Vaccine

IS - 52

ER -

Developing the next generation of vaccinologists

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this